Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 9:38 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 1,567 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Regimen Clear all
Recruiting Phase 1Phase 2 Interventional

A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve Damage

NCT07770685
View directory record Official record
Conditions
Glaucoma
Interventions
ASP2767, Sham ASP2767, Prophylactic Regimen A, Prophylactic Regimen B, Placebo for prophylactic regimen
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 1, 2026, 9:38 AM EST
Completed Phase 3 Interventional Results available

Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures

NCT00334958
View directory record Official record
Conditions
Epilepsy
Interventions
Placebo, Rufinamide
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 80 Years
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
77
States / cities
Mobile, Alabama • Northport, Alabama • Phoenix, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Nov 1, 2026, 9:38 AM EST
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease

NCT02760433
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Olokizumab, Placebo
Drug
Lead sponsor
R-Pharm International, LLC
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Covina, California + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Nov 1, 2026, 9:38 AM EST
Active, not recruiting Not applicable Interventional

Insulin Detemir in Obesity Management

NCT01239550
View directory record Official record
Conditions
Diabetes, Obesity
Interventions
Detemir
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
31 Years to 60 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Nov 1, 2026, 9:38 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Mobilization in Conjunction With Therapeutic Exercise in Participants With a History of Ankle Sprain

NCT02945943
View directory record Official record
Conditions
Functional Deficits, Manipulation, Rehabilitation
Interventions
High Velocity Low Amplitude mobilization, Exercise Protocol
Other
Lead sponsor
Shenandoah University
Other
Eligibility
16 Years to 35 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Winchester, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Nov 1, 2026, 9:38 AM EST
Completed Not applicable Interventional

Exercise Training Study for Patients With Cystic Fibrosis

NCT00609050
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Self-Regulated Exercise with Telephone Reinforcement, Standard Treatment, Qualitative Approach
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
10 Years to 18 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2016 · Synced Nov 1, 2026, 9:38 AM EST
Completed Phase 3 Interventional Results available

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)

NCT05850520
View directory record Official record
Conditions
Macular Edema Secondary to Retinal Vein Occlusion
Interventions
Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Sham, Fluorescein
Drug · Diagnostic Test
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
892 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
53
States / cities
Fullerton, California • Long Beach, California • Mountain View, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Nov 1, 2026, 9:38 AM EST
Recruiting Phase 4 Interventional

Efficacy of Methylprednisolone for Pain Control After ACL Repair

NCT07158476
View directory record Official record
Conditions
ACL Surgery, Pain Management
Interventions
Meloxicam 15 mg, Medrol 4 MG Oral Tablet Includes Medrol Dosepak, Gabapentin 300 mg, Hydrocodone 5Mg/Acetaminophen 325Mg Tab, Ketorolac 10 Mg Oral Tablet
Drug
Lead sponsor
St. Louis University
Other
Eligibility
13 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Nov 1, 2026, 9:38 AM EST
Terminated Phase 2 Interventional

Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 Diabetes

NCT00698789
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
INCB019602, Placebo, Metformin
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
22
States / cities
Phoenix, Arizona • Tucson, Arizona • Chula Vista, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Nov 1, 2026, 9:38 AM EST
Completed Not applicable Interventional Results available

Stroke Education Intervention Trial - Pilot

NCT01115660
View directory record Official record
Conditions
Ischemic Stroke, Intracranial Hemorrhage, Transient Ischemic Attack
Interventions
stroke education
Behavioral
Lead sponsor
Duke University
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Nov 1, 2026, 9:38 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers

Ketamine for Endoscopic Sedation in Outpatient Adult Endoscopy.

NCT03461718
View directory record Official record
Conditions
Administration and Dosage of Ketamine, Endoscopic Sedation
Interventions
Ketamine, Midazolam injection, Fentanyl
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Nov 1, 2026, 9:38 AM EST
Completed Phase 1Phase 2 Interventional

Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

NCT05747924
View directory record Official record
Conditions
FSHD, FSHD1, FSHD2, FMD, FMD2, Fascioscapulohumeral Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy Type 1, Fascioscapulohumeral Muscular Dystrophy Type 2, Dystrophies, Facioscapulohumeral Muscular, Dystrophy, Facioscapulohumeral Muscular, Facioscapulohumeral Muscular Dystrophy 1, Facioscapulohumeral Muscular Dystrophy 2, Facio-Scapulo-Humeral Dystrophy, Atrophy, Facioscapulohumeral, Atrophies, Facioscapulohumeral, Facioscapulohumeral Atrophy, Muscular Dystrophies, Muscular Dystrophy, Facioscapulohumeral, FSH Muscular Dystrophy, Landouzy Dejerine Dystrophy, Landouzy-Dejerine Muscular Dystrophy, Dystrophies, Landouzy-Dejerine, Dystrophy, Landouzy-Dejerine, Landouzy-Dejerine Syndrome, Muscular Dystrophy, Landouzy Dejerine, Progressive Muscular Dystrophy, FSH
Interventions
AOC 1020, Placebo
Drug
Lead sponsor
Avidity Biosciences, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 1, 2026, 9:38 AM EST
Completed Phase 2 Interventional Results available

Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only

NCT00518115
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Albiglutide (GSK716155) or exenatide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
158
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 142 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Nov 1, 2026, 9:38 AM EST
Recruiting Not applicable Interventional

Heuristic Tool To Improve Symptom Self-Management in Adolescents and Young Adults With Cancer

NCT05958316
View directory record Official record
Conditions
Symptoms and Signs, Cancer, Childhood Cancer
Interventions
Computerized Symptom Capture Tool (C-SCAT) Intervention, Usual Care Control
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
15 Years to 29 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Kansas City, Missouri • Salt Lake City, Utah • Richmond, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 1, 2026, 9:38 AM EST
Completed Phase 3 Interventional Results available

An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment

NCT01064414
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Renal Insufficiency
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
25 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
26
States / cities
Concord, California • Fountain Valley, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2013 · Synced Nov 1, 2026, 9:38 AM EST
Completed Phase 2 Interventional Results available

A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight

NCT06712836
View directory record Official record
Conditions
Obesity, Overweight or Obesity
Interventions
MET097, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Anaheim, California • Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Nov 1, 2026, 9:38 AM EST
Active, not recruiting Phase 3 Interventional

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

NCT03165734
View directory record Official record
Conditions
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions
Pacritinib, Physician's Choice medications
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Nov 1, 2026, 9:38 AM EST
Completed Phase 2 Interventional

The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage

NCT00991198
View directory record Official record
Conditions
Rosacea, Acne Vulgaris, Atopic Dermatitis, Seborrheic Dermatitis
Interventions
Topical oxygen, placebo
Drug
Lead sponsor
Aria Aesthetics Inc.
Industry
Eligibility
25 Years to 60 Years · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Nov 1, 2026, 9:38 AM EST
Terminated Phase 2 Interventional Results available

Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC

NCT04786093
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Stereotactic radiation therapy, Durvalumab
Radiation · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Nov 1, 2026, 9:38 AM EST
Completed Phase 3 Interventional Results available

Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes

NCT00982228
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin degludec, insulin glargine, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
59
States / cities
Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Nov 1, 2026, 9:38 AM EST
Active, not recruiting Phase 3 Interventional

A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer

NCT03899636
View directory record Official record
Conditions
Stage III Pancreatic Cancer
Interventions
Modified FOLFIRINOX Regimen, NanoKnife System
Drug · Device
Lead sponsor
Angiodynamics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Miami, Florida • Tampa, Florida • Arlington Heights, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Nov 1, 2026, 9:38 AM EST
Withdrawn Phase 4 Interventional

Effect of a Multimodal Pain Regimen on Pain Control, Patient Satisfaction and Narcotic Use in Orthopaedic Trauma Patients

NCT02160301
View directory record Official record
Conditions
Post Operative Pain Control
Interventions
Gabapentin, Acetaminophen, Celecoxib, Dexamethasone, Oxycodone
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Nov 1, 2026, 9:38 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Controlled Study Comparing REPaiR® and MIST Therapies for Treatment of Periodontitis

NCT04169139
View directory record Official record
Conditions
Periodontal Diseases
Interventions
MIST (minimally invasive surgical therapy)
Device
Lead sponsor
McGuire Institute
Industry
Eligibility
18 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Nov 1, 2026, 9:38 AM EST
Terminated Phase 1Phase 2 Interventional Results available

Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

NCT03610581
View directory record Official record
Conditions
Human Papillomavirus Infections
Interventions
Ad26.HPV16, Ad26.HPV18, MVA.HPV16/18, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Doral, Florida • Fort Myers, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Nov 1, 2026, 9:38 AM EST